share_log

The Latest Analyst Ratings For Legend Biotech

Benzinga ·  Jul 16 01:00

In the preceding three months, 15 analysts have released ratings for Legend Biotech (NASDAQ:LEGN), presenting a wide array of perspectives from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings105000
Last 30D10000
1M Ago23000
2M Ago40000
3M Ago32000

The 12-month price targets, analyzed by analysts, offer insights with an average target of $78.93, a high estimate of $90.00, and a low estimate of $60.00. Highlighting a 2.56% decrease, the current average has fallen from the previous average price target of $81.00.

1721062814_0.png

Interpreting Analyst Ratings: A Closer Look

In examining recent analyst actions, we gain insights into how...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment